HLS Therapeutics (TSE:HLS) Shares Up 0.4% - What's Next?

Key Points

• HLS Therapeutics shares increased by 0.4%, closing at C$5.61 after trading as high as C$5.68 with a volume decline of 41% from the average.
• Raymond James Financial upgraded the stock from a "hold" to a "moderate buy" and raised the target price from C$5.00 to C$6.00.
• The company, focused on specialty pharmaceuticals for CNS and cardiovascular treatments, has a current market capitalization of C$176.12 million.

HLS Therapeutics Inc. (TSE:HLS - Get Free Report) shot up 0.4% on Monday . The company traded as high as C$5.68 and last traded at C$5.61. 7,465 shares were traded during trading, a decline of 41% from the average session volume of 12,701 shares. The stock had previously closed at C$5.59.

Analyst Ratings Changes

Separately, Raymond James Financial raised shares of HLS Therapeutics from a "hold" rating to a "moderate buy" rating and boosted their target price for the stock from C$5.00 to C$6.00 in a research note on Thursday, August 21st. One equities research analyst has rated the stock with a Hold rating, Based on data from MarketBeat, HLS Therapeutics has an average rating of "Hold" and an average target price of C$5.00.

HLS Therapeutics Stock Up 0.4%

The firm has a market capitalization of C$176.12 million, a price-to-earnings ratio of -11.69 and a beta of 0.65. The stock has a fifty day moving average of C$5.15 and a two-hundred day moving average of C$4.75. The company has a debt-to-equity ratio of 86.50, a current ratio of 1.56 and a quick ratio of 1.01.

About HLS Therapeutics

HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company is focused on treatment products for the central nervous system (CNS), and cardiovascular specialties. The company products include Clozaril, Absorica, Vascepa, CSAN Pronto, Trinomia and Perseris.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.